Analytica Ltd. announced publication of an independent clinical trial from The University of New Mexico in the Journal of Female Pelvic Medicine & Reconstructive Surgery, the official journal of the American Urogynecologic Society, demonstrating PeriCoach non-inferiority to in- clinic pelvic floor physical therapy. The randomised single-centre study, led by principal investigator Dr. Lauren de Winter (formerly Barnes), was designed to assess if home biofeedback is non-inferior to standard of care supervised pelvic floor physical therapy (PFPT) for the treatment of stress urinary incontinence (SUI) in women who desire non- surgical therapy. The 48-participant study compared the use of a PeriCoach personal biofeedback device with PFPT. PFPT has proven to be an effective tool for reducing SUI symptoms and improving quality of life. However, women living in remote areas, or who cannot afford, do not wish to access, or have otherwise limited access to PFPT may need alternative treatment options to gain the same benefits of monitored pelvic floor rehabilitation. The goal of the study was also to support the implementation of personal biofeedback devices to overcome issues with patient distance and ability to maintain clinician monitoring. The PeriCoach feature set of technique guidance technology, the unique ability to measure muscle strength directly, comprehensive measurement and data analytics, and clinical connectivity features were able to meet these challenges. The primary outcome measurement was met, with the biofeedback group using PeriCoach demonstrating non-inferiority to PFPT based on quality of life score as measured by the International Consultation on Incontinence Questionnaire short form (ICIQ-SF). For the primary outcome of change in ICIQ-SF scores (where lower scores indicate less urinary incontinence), the home biofeedback group using PeriCoach was found to be non-inferior to PFPT [-4.73 (-3.21 to -6.25) vs -3.95 (-2.21 to -5.70), p= 0.009].